Managing side effects of tyrosine kinase inhibitor therapy to optimize adherence in patients with chronic myeloid leukemia: The role of the midlevel practitioner

Journal of Supportive Oncology

Volumn 10, Issue 1, 2012, Pages 14-23

  Cornelison, Megan ^a   Jabbour, Elias J ^a   Welch, Mary Alma ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DASATINIB; IMATINIB; NILOTINIB;

ABDOMINAL PAIN; ALOPECIA; ANEMIA; ARTHRALGIA; ARTICLE; ASTHENIA; BACKACHE; BLEEDING; BONE PAIN; BRAIN HEMORRHAGE; CANCER SURVIVAL; CHRONIC MYELOID LEUKEMIA; CONGESTIVE HEART FAILURE; CONSTIPATION; COUGHING; DEPRESSION; DIARRHEA; DIZZINESS; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; EDEMA; FATIGUE; FEVER; FLUID RETENTION; GASTROINTESTINAL HEMORRHAGE; HEADACHE; HUMAN; HYPERTRANSAMINASEMIA; HYPOPHOSPHATEMIA; INFLUENZA; INSOMNIA; LUNG EDEMA; MUSCLE CRAMP; MUSCLE SPASM; MUSCULOSKELETAL PAIN; MYALGIA; MYOSITIS; NAUSEA; NEUTROPENIA; NURSE PRACTITIONER; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PATIENT CARE; PATIENT COMPLIANCE; PATIENT EDUCATION; PATIENT MONITORING; PERICARDIAL EFFUSION; PERIPHERAL EDEMA; PHARMACIST ATTITUDE; PHYSICIAN ASSISTANT; PLEURA EFFUSION; PRURITUS; PULMONARY HYPERTENSION; QT PROLONGATION; QUALITY OF LIFE; RASH; RHINOPHARYNGITIS; SIDE EFFECT; SINUSITIS; SORE THROAT; SURVIVAL RATE; THROMBOCYTOPENIA; UPPER ABDOMINAL PAIN; UPPER RESPIRATORY TRACT INFECTION; VOMITING; WEIGHT GAIN;

ANTINEOPLASTIC AGENTS; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MEDICATION ADHERENCE; PATIENT EDUCATION AS TOPIC; PROFESSIONAL ROLE; PROTEIN-TYROSINE KINASES;

EID: 84855788761     PISSN: 15446794     EISSN: 1879596X     Source Type: Journal    
DOI: 10.1016/j.suponc.2011.08.001     Document Type: Article

References (71)

1. Cervantes F., Hernandez-Boluda J.C., Ferrer A., et al. The changing profile of Ph-positive chronic myeloid leukemia at presentation: possible impact of earlier diagnosis on survival. Haematologica 1999, 84:324-327.
2. Breed C.D. Diagnosis, treatment, and nursing care of patients with chronic leukemia. Semin Oncol Nurs 2003, 19:109-117.
3. Rohrbacher M., Hasford J. Epidemiology of chronic myeloid leukaemia (CML). Best Pract Res Clin Haematol 2009, 22:295-302.
4. Heisterkamp N., Stam K., Groffen J., et al. Structural organization of the bcr gene and its role in the Ph' translocation. Nature 1985, 315:758-761.
5. Mauro M.J., Druker B.J. STI571: targeting BCR-ABL as therapy for CML. Oncologist 2001, 6:233-238.
6. McLaughlin J., Chianese E., Witte O.N. In vitro transformation of immature hematopoietic cells by the P210 BCR/ABL oncogene product of the Philadelphia chromosome. Proc Natl Acad Sci USA 1987, 84:6558-6562.
7. Huguley C.M., Grizzle J., Rundles R.W., et al. Comparison of 6-mercaptopurine and busulfan in chronic granulocytic leukemia. Blood 1963, 21:89-101. Southeastern Cancer Chemotherapy Cooperative Study Group.
8. Interferon alfa versus chemotherapy for chronic myeloid leukemia: a meta-analysis of seven randomized trials: Chronic Myeloid Leukemia Trialists' Collaborative Group. J Natl Cancer Inst 1997, 89:1616-1620. CML Trialists' Collaborative Group.
9. Talpaz M., Kantarjian H.M., McCredie K., et al. Hematologic remission and cytogenetic improvement induced by recombinant human interferon alpha A in chronic myelogenous leukemia. N Engl J Med 1986, 314:1065-1069.
10. Allan N.C., Richards S.M., Shepherd P.C. UK Medical Research Council randomised, multicentre trial of interferon-alpha n1 for chronic myeloid leukaemia: improved survival irrespective of cytogenetic response. The UK Medical Research Council's Working Parties for Therapeutic Trials in Adult Leukaemia. Lancet 1995, 345:1392-1397.
11. Marin D., Bazeos A., Mahon F.X., et al. Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. J Clin Oncol 2010, 28:2381-2388.
12. Noens L., van Lierde M.A., De Bock R., et al. Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study. Blood 2009, 113:5401-5411.
13. Osterberg L., Blaschke T. Adherence to medication. N Engl J Med 2005, 353:487-497.
14. Awofeso N. Anti-tuberculosis medication side-effects constitute major factor for poor adherence to tuberculosis treatment. Bull World Health Organ 2008, 86. B-D.
15. Cerasoli F. Developing the ideal inhaled corticosteroid. Chest 2006, 130:54S-64S.
16. Elliott W.J. What factors contribute to the inadequate control of elevated blood pressure?. J Clin Hypertens (Greenwich) 2008, 10:20-26.
17. Menzies D., Long R., Trajman A., et al. Adverse events with 4 months of rifampin therapy or 9 months of isoniazid therapy for latent tuberculosis infection: a randomized trial. Ann Intern Med 2008, 149:689-697.
18. Murphy D.A., Sarr M., Durako S.J., et al. Barriers to HAART adherence among human immunodeficiency virus-infected adolescents. Arch Pediatr Adolesc Med 2003, 157:249-255.
19. Schrader S., Chuck S.K., Rahn L.W., et al. Significant improvements in self-reported gastrointestinal tolerability, quality of life, patient satisfaction, and adherence with lopinavir/ritonavir tablet formulation compared with soft gel capsules. AIDS Res Ther 2008, 5:21.
20. Eliasson L., Clifford S., Barber N., et al. Exploring chronic myeloid leukemia patients' reasons for not adhering to the oral anticancer drug imatinib as prescribed. Leuk Res 2010, 35:626-630.
21. O'Brien S.G., Guilhot F., Larson R.A., et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003, 348:994-1004.
22. Shah N.P. Medical management of CML. Hematology Am Soc Hematol Educ Program 2007, 371-375.
23. Kantarjian H.M., Giles F., Gattermann N., et al. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood 2007, 110:3540-3546.
24. le Coutre P., Ottmann O.G., Giles F., et al. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia. Blood 2008, 111:1834-1839.
25. Kantarjian H., Pasquini R., Hamerschlak N., et al. Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial. Blood 2007, 109:5143-5150.
26. SEER cancer statistics review, 1975-2002 2004, vol. 2010. National Cancer Institute, Bethesda, MD, Based on November 2004 SEER data submission, posted to the SEER web site 2005. L. Ries, M. Eisner, C. Kosary (Eds.).
27. SEER cancer statistics review, 1975-2007 2010, vol. 2010. National Cancer Institute, Bethesda, MD, Based on November 2009 SEER data submission, posted to the SEER web site 2010. S. Altekruse, C. Kosary, M. Krapcho (Eds.).
28. Deininger M., O'Brien S.G., Guilhot F., et al. International Randomized Study of Interferon Vs STI571 (IRIS) 8-year follow up: sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib. Blood 2009, 114:1126. ASH Annual Meeting Abstracts.
29. Saglio G., Kim D.W., Issaragrisil S., et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 2010, 362:2251-2259.
30. Hughes T.P., Hochhaus A., Saglio G., et al. ENESTnd update: continued superiority of nilotinib versus imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP). Blood 2010, 116:207. ASH Annual Meeting Abstracts.
31. Larson R.A., Kim D., Rosti G., et al. Comparison of nilotinib and imatinib in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): ENESTnd 24-month follow-up. J Clin Oncol 2011, 29:6511. Meeting Abstracts.
32. Kantarjian H., Shah N.P., Hochhaus A., et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2010, 362:2260-2270.
33. Shah N., Kantarjian H., Hochhaus A., et al. Dasatinib versus imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) in the DASISION trial: 18-month follow-up. Blood 2010, 116:206. ASH Annual Meeting Abstracts.
34. O'Brien S., Berman E., Moore J.O., et al. NCCN Task Force Report. Tyrosine kinase inhibitor therapy selection in the management of patients with chronic myelogenous leukemia. J Natl Compr Canc Netw 2011, 9(2 suppl):S1-S25.
35. Williams L.A., Ault P., Cleeland C.S., et al. Symptom burden in chronic myeloid leukemia (CML). J Clin Oncol 2010, 28:6133. Meeting Abstracts.
36. Sprycel® (dasatinib) prescribing information 2010, Bristol-Myers Squibb Company.
37. Gleevec® (imatinib mesylate) prescribing information 2008, Novartis.
38. Tasigna® (nilotinib) prescribing information 2010, Novartis.
39. Druker B.J., Guilhot F., O'Brien S.G., et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006, 355:2408-2417.
40. Larson R.A., Hochhaus A., Saglio G., et al. Cardiac safety profile of imatinib and nilotinib in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): results from ENESTnd. Blood 2010, 116:2291. ASH Annual Meeting Abstracts.
41. Kantarjian H.M., Giles F.J., Bhalla K.N., et al. Update on imatinib-resistant chronic myeloid leukemia patients in chronic phase (CML-CP) on nilotinib therapy at 24 months: clinical response, safety, and long-term outcomes. Blood 2009, 114:1129. ASH Annual Meeting Abstracts.
42. Kantarjian H.M., Talpaz M., O'Brien S., et al. Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia. Blood 2003, 101:473-475.
43. National Comprehensive Cancer Network: Clinical Practice Guidelines in Oncology. Chronic Myelogenous Leukemia 2011, NCCN, Version 1.2012, National Comprehensive Cancer Network, Fort Washington, PA.
44. Zonder J.A., Pemberton P., Brandt H., et al. The effect of dose increase of imatinib mesylate in patients with chronic or accelerated phase chronic myelogenous leukemia with inadequate hematologic or cytogenetic response to initial treatment. Clin Cancer Res 2003, 9:2092-2097.
45. Tanaka C., Yin O.Q., Sethuraman V., et al. Clinical pharmacokinetics of the BCR-ABL tyrosine kinase inhibitor nilotinib. Clin Pharmacol Ther 2010, 87:197-203.
46. Mauro M.J., Deininger M.W. Management of drug toxicities in chronic myeloid leukaemia. Best Pract Res Clin Haematol 2009, 22:409-429.
47. Quintas-Cardama A., Kantarjian H., O'Brien S., et al. Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure. J Clin Oncol 2007, 25:3908-3914.
48. Masiello D., Gorospe G., Yang A.S. The occurrence and management of fluid retention associated with TKI therapy in CML, with a focus on dasatinib. J Hematol Oncol 2009, 2:46.
49. Hochhaus A., O'Brien S.G., Guilhot F., et al. Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia 2009, 23:1054-1061.
50. Petzer A.L., Wolf D., Fong D., et al. High-dose imatinib improves cytogenetic and molecular remissions in patients with pretreated Philadelphia-positive, BCR-ABL-positive chronic phase chronic myeloid leukemia: first results from the randomized CELSG phase III CML 11 "ISTAHIT" study. Haematologica 2010, 95:908-913.
51. Castagnetti F., Palandri F., Amabile M., et al. Results of high-dose imatinib mesylate in intermediate Sokal risk chronic myeloid leukemia patients in early chronic phase: a phase 2 trial of the GIMEMA CML Working Party. Blood 2009, 113:3428-3434.
52. Kaplan S.H., Greenfield S., Ware J.E. Assessing the effects of physician-patient interactions on the outcomes of chronic disease. Med Care 1989, 27(3 suppl):S110-S127.
53. Haouala A., Widmer N., Duchosal M.A., et al. Drug interactions with the tyrosine kinase inhibitors imatinib, dasatinib, and nilotinib. Blood 2011, 117:e75-e87.
54. Hollywood E., Semple D. Nursing strategies for patients on oral chemotherapy. Oncology (Williston Park) 2001, 15:37-40.
55. La Rosee P., Leitner A., Martiat P., et al. Weekend drug holiday of dasatinib in CML patients not tolerating standard dosing regimens. Reducing toxicity with maintained disease control. Abstract presented at the American Society of Hematology Annual Meeting 2009.
56. DiMatteo M.R., Giordani P.J., Lepper H.S., et al. Patient adherence and medical treatment outcomes: a meta-analysis. Med Care 2002, 40:794-811.
57. Ruddy K., Mayer E., Partridge A. Patient adherence and persistence with oral anticancer treatment. CA Cancer J Clin 2009, 59:56-66.
58. Chung M.H., Richardson B.A., Tapia K., et al. A randomized controlled trial comparing the effects of counseling and alarm device on HAART adherence and virologic outcomes. PLoS Med 2011, 8:e1000422.
59. Ryan R., Santesso N., Hill S., et al. Consumer-oriented interventions for evidence-based prescribing and medicines use: an overview of systematic reviews. Cochrane Database Syst Rev 2011, 5. CD007768.
60. Guilhot F., Coombs J., Zernovak O., et al. A global retrospective and physician-based analysis of adherence to tyrosine kinase inhibitor (TKI) therapies for chronic myeloid leukemia (CML). Blood 2010, 116:1514. ASH Annual Meeting Abstracts.
61. Wensing M. Evidence-based patient empowerment. Qual Health Care 2000, 9:200-201.
62. Max B., Sherer R. Management of the adverse effects of antiretroviral therapy and medication adherence. Clin Infect Dis 2000, 30(2 suppl):S96-S116.
63. Spirig R., Moody K., Battegay M., et al. Symptom management in HIV/AIDS: advancing the conceptualization. ANS Adv Nurs Sci 2005, 28:333-344.
64. Stone V.E. Strategies for optimizing adherence to highly active antiretroviral therapy: lessons from research and clinical practice. Clin Infect Dis 2001, 33:865-872.
65. Cortes J., O'Brien S., Kantarjian H. Discontinuation of imatinib therapy after achieving a molecular response. Blood 2004, 104:2204-2205.
66. Mahon F.-X., Réa D., Guilhot J., et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol 2010, 11:1029-1035.
67. Cortes J., Kantarjian H.M., Baccarani M., et al. A phase 1/2 study of SKI-606, a dual inhibitor of Src and Abl kinases, in adult patients with Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia (CML) or acute lymphocytic leukemia (ALL) relapsed, refractory or intolerant of imatinib. Blood 2006, 108:168. ASH Annual Meeting Abstracts.
68. Bebbington D., Binch H., Charrier J.D., et al. The discovery of the potent aurora inhibitor MK-0457 (VX-680). Bioorg Med Chem Lett 2009, 19:3586-3592.
69. Gontarewicz A., Brummendorf T.H. Danusertib (formerly PHA-739358)-a novel combined pan-Aurora kinases and third generation Bcr-Abl tyrosine kinase inhibitor. Recent Results Cancer Res 2010, 184:199-214.
70. Cortes J., Talpaz M., Bixby D., et al. A phase 1 trial of oral ponatinib (AP24534) in patients with refractory chronic myelogenous leukemia (CML) and other hematologic malignancies: emerging safety and clinical response findings. Blood 2010, 116:210. ASH Annual Meeting Abstracts.
71. Jabbour E., Fullmer A., Cortes J.E., et al. Clinical algorithms for the treatment of patients with chronic myeloid leukemia: the 2010 perspective. Clin Lymphoma Myeloma Leuk 2010, 10(1 suppl):S6-S13.